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Preclinical stroke models provide insights into mechanisms of cellular injury and potential
therapeutic targets. Renewed efforts to standardize preclinical practices and adopt more
rigorous approaches reﬂect the assumption that a better class of compounds will trans-
late into clinical efﬁcacy. While the need for novel therapeutics is clear, it is also critical
that diagnostics be improved to allow for more rapid treatment upon hospital admission.
Advances in imaging techniques have aided in the diagnosis of stroke, yet current limitations
and expenses demonstrate the need for new and complementary approaches. Intracere-
bral hemorrhage (ICH) exhibits the highest mortality rate, displays unique pathology and
requires specialized treatment strategies relative to other forms of stroke. The aggres-
sive nature and severe consequences of ICH underscore the need for novel therapeutic
approaches as well as accurate and expeditious diagnostic tools. The use of experimental
models will continue to aid in addressing these important issues as the ﬁeld attempts to
translate basic science ﬁndings into the clinical setting. Several preclinical models of ICH
have been developed and are widely used to recapitulate human pathology. Because each
model has limitations, the burden lies with the investigator to clearly deﬁne the question
being asked and select the model system that is most relevant to that question. It may also
be necessary to optimize and reﬁne pre-existing paradigms, or generate new paradigms,
as the future success of translational research is dependent upon the ability to mimic
human sequelae and assess clinically relevant outcome measures as means to evaluate
therapeutic efﬁcacy.
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INTRODUCTION
Preclinical studies are the foundation for drug development and
the primary basis upon which to deﬁne mechanism of action, yet
the success of animal studies is immaterial if efﬁcacy is lost or
toxicity occurs in patient populations. The ﬁeld of central nervous
research,most notably stroke, has been plagued by promising pre-
clinical data for compounds that disappoint when applied in the
clinical setting. The blame for these translational discrepancies has
been assigned, in large part, to poor study design in both research
sectors. For example, inappropriate statistical analyses, underpow-
ered studies, experimenter bias, lack of validation studies, lack
of comorbid conditions, and inappropriate cohort selection are
just a few of the attributed causes (STAIR, 1999; STAIR-II, 2001;
O’Collins et al., 2006; Fisher et al., 2009).
Over the past decade, resurgence in methodological inquiry has
prompted detailed investigations into experimental design in both
the basic science (STAIR,1999;Dirnagl, 2010) and clinical research
(STAIR-II, 2001) environments. Out of these inquiries arose sev-
eral important realizations regarding the manner in which pre-
clinical studies should be conducted, with a renewed emphasis
on various aspects that ultimately relate to whether experimen-
tal paradigms resemble the human condition. Several important
points have also been raised regarding methods to improve clinical
trial design, though these will not be discussed here. While many
of the guidelines and recommendations for preclinical studies
were framed within the context of ischemic stroke, most are
directly applicable to hemorrhagic stroke, including intracerebral
hemorrhage (ICH).
A thoughtful approach to conducting the most rigorous, clin-
ically relevant preclinical studies inevitably centers upon whether
the models under scrutiny recapitulate aspects of the clinical
pathology that ultimately reduce the quality of daily living in stroke
patients. As such, the future success of novel therapeutics neces-
sarily hinges upon the relevance of the models in which they are
tested and the outcomes by which efﬁcacy is assessed. With this
in mind, it is clear that translating preclinical successes to patient
populations is not untenable; rather, it requires careful consid-
eration of experimental paradigms and methodological practices
(MacLellan et al., 2012). The pages that follow highlight several
aspects of clinical ICH pathology and identiﬁed risk factors that
have been or should be incorporated into experimental studies.
Future directions are then discussed within the contexts of devel-
oping diagnostic tools and modeling risk factors. Together, these
approaches should improve the overall quality and translational
value of preclinical ICH investigations.
CLINICAL ASPECTS OF INTRACEREBRAL HEMORRHAGE
Stroke currently accounts for 73.7 billion dollars in annual med-
ical costs and is the fourth leading cause of death in the United
States. Approximately 13% of strokes occur through some type of
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hemorrhage, resulting in blood leakage into the brain parenchyma
or subarachnoid space and subsequent injury by virtue of exces-
sive cerebral pressure and various mechanisms of cellular toxicity.
Although it constitutes the minority of stroke cases, hemorrhagic
stroke claims the most lives with 30–40% mortality, half of which
occurs within 2 days of onset (Roger et al., 2012). Several unique
circumstancesmay lead to hemorrhage of a cerebral artery, includ-
ing β-amyloid deposition and associated microbleeds (Hartz et al.,
2012; Smith et al., 2012), brain trauma (Eisenberg et al., 1990; Ser-
vadei et al., 2002), hemorrhagic transformation following embolic
stroke (Rosell et al., 2008; England et al., 2010), or physiological
abnormalities in vessel stability and integrity. In all cases, the com-
mon denominator is weakened arterial vasculature that eventually
ruptures.
The primary goals of experimental research are to (1) eluci-
date the biological mechanisms that mediate injury progression,
and (2) identify, develop, and test novel therapies that can be
applied in the clinical setting to improve patient outcomes. These
goals are achieved primarily through use of experimental mod-
els that recapitulate certain aspects of ICH pathology, which may
include mimicking vascular abnormalities, hematoma expansion,
and/or inﬂammatory responses. Although ICH can result from
many causes, some of which remain unknown, several aspects of
ICH pathology have been well-characterized and demonstrated to
account for a great many cases within the clinical setting.
VASCULAR ABNORMALITIES
The most common vascular abnormalities associated with hem-
orrhagic stroke are aneurysms and arteriovenous malformations
(AVMs), each of which can lead to ICH (Farhat, 2011) or sub-
arachnoid hemorrhage (SAH) depending upon the location of
the vessel. Furthermore, the size and location of the affected ves-
sel is directly related to the severity of the injury, with larger,
deeper-seated vessels producing greater devastation upon rupture.
Although aneurysms and AVMs both involve swelling of weak-
ened vessels, cerebral aneurysms are often characterized as “bal-
looning” vessels. Aneurysms typically manifest after the age of
40, and are generally asymptomatic (0.5–3% result in bleeding)
despite the fact that they account for the majority of SAH cases.
AVMs are characterized by tangled arterial vessels that bypass
the brain, consequently diverting oxygenated blood directly into
the venous circulation. These atypical vessels dilate and weaken
over time, and eventually succumb to high arterial blood pres-
sure. In contrast to aneurysms, which develop over time and are
typically located within the deep cerebral vasculature, AVMs are
congenital (but are not generally considered heritable) and can
develop anywhere within the brain or on its surface (modiﬁed
from strokeassociation.org).
Upon considering the vast spectrum of causes, including vary-
ing degrees of brain trauma, vascular abnormalities, β-amyloid
depositions, and embolic occlusions, it is no surprise that hemor-
rhage produces awide range of neuropathies. Indeed,hemorrhagic
insult can manifest as motor disturbances, speech impairments,
emotional impulsivity, and/or learning and memory dysfunction.
Within the general context of stroke, the most recent data indi-
cates that the incidence of ICH is approximately 10% compared
to 3% for SAH (Roger et al., 2012). Moreover, ICH is particularly
devastating since blood extravasation into the brain causes cellular
toxicity in addition to the accumulation of intracranial pressure.
In the preclinical setting, these factors weigh heavily upon the
experimental models employed, the outcome measures assessed
and the treatment modalities tested (these issues will be discussed
at length in subsequent sections). As clinicians reﬁne their treat-
ment strategies using experience and the best available imaging
techniques, basic scientists continue to search for novel thera-
pies using the most clinically relevant models and methodological
approaches. In spite of these efforts, a stroke occurs approxi-
mately every 40 s (strokeassociation.org), and therefore the most
effective means to combat stroke in the immediate sense may be
through identiﬁcation of risk factors, lifestyle alterations, and early
diagnosis upon admission to the clinic.
PLAQUE DEPOSITION AND MICROBLEEDS
Deposition of plaques within the vascular lumen can weaken
vascular integrity, resulting in leaky vessels and eventual rup-
ture. Cerebral amyloid angiopathy (CAA), characterized by the
deposition of β-amyloid fragmentswithin the cerebral arterial vas-
culature, has been linked to hemorrhage (Smith and Greenberg,
2009; Vasilevko et al., 2010). This pathology increases over time
in the elderly population and is predominantly localized to the
posterior lobar regions of the brain (Vinters and Gilbert, 1983).
These amyloid deposits produce vascular pathology, including
alterations in vessel wall thickness and lumen diameter, that are
associated with impaired cognitive function (Zekry et al., 2003)
either in the presence or absence of Alzheimer Disease (Vinters
and Gilbert, 1983).
The degree of CAA correlates with ICH, with microa-
neurysms resulting from excessive plaque loads (Vonsattel et al.,
1991). Indeed, microhemorrhages are directly related to cogni-
tive deﬁcits associated with the accumulation of plaques and have
been demonstrated to predict subsequent hemorrhagic episodes
(Greenberg et al., 2004). Interestingly, diffusion-weighted mag-
netic resonance imaging (MRI) has demonstrated the ability to
detect hyperintensities that represent subacute infarctions within
the cerebral cortex and subcortical white matter of advanced CAA
patients (Kimberly et al., 2009). While it stands to reason that the
degree of subacute infarction would correlate with hemorrhage
burden, it will be interesting to determine whether these “silent”
infarctions (Smith et al., 2012) can provide any information
regarding disease etiology or progression (for a comprehensive
review of CAA, see Viswanathan and Greenberg, 2011).
RISK FACTORS AND DIAGNOSTICS
Of the many stroke risk factors identiﬁed to date, it is perhaps
most helpful to consider those which can be controlled as we
seek more effective strategies to prevent ICH. For example, high
blood pressure is the leading cause of stroke, and lowering blood
pressure reduced the risk of hypertension-related ICH and CAA-
related ICH (Arima et al., 2010). Diabetes, smoking, and high
blood cholesterol are also major risk factors since these conditions
are often accompanied by high blood pressure and buildup of
atherosclerotic plaques. In particular, diabetes and hyperglycemia
are associated with increased risk for hemorrhagic transformation
in patients with ischemic stroke (Poppe et al., 2009; Kruyt et al.,
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2010). Because the hallmark of ICH is pressure-induced rupturing
of weakened vessels, lifestyle alterations including increased exer-
cise and adopting a healthier diet are relatively simple, yet effec-
tive, means of preventing atherosclerosis and controlling blood
pressure. High blood pressure often occurs in conjunction with
diabetes, which is also a major risk factor for ICH.
In spite of these preventative strategies, there are other inherent
risks and uncontrollable factors associated with age, sex, race, and
others (for current comprehensive data concerning risk factors,
see the most recent report from the American Heart Association;
Roger et al., 2012). Because risk for stroke can be partly dependent
upon genetic factors and age, it is imperative to improve diagnos-
tics and treatment strategies in addition to adopting preventative
measures. Importantly, ICH exhibits unique characteristics that
render the brain more susceptible to injury, as reﬂected by the high
mortality rate relative to other stroke sub-types. For this reason,
it is critically important to develop effective tools that can quickly
identify cerebral hemorrhage, as well as circumstances that signify
a substantial risk for ICH in patients suffering from other types of
stroke.
In the current clinical setting, time is of the essence due to the
narrow therapeutic window for thrombolytic therapy and the high
mortality rate associated with ICH. Several diagnostic approaches
are employed to eliminate confounding causes of stroke symptoms
and accurately identify the type of stroke prior to the initiation of
any therapy. This latter point is critical since ischemic and hemor-
rhagic strokes require distinct treatment modalities, and incorrect
diagnosis may not only be ineffective but may actually worsen the
outcome (i.e., administration of tissue plasminogen activator in
cases of ICH). The initial patient evaluation most often includes
a physical assessment, analysis of patient history, brain imaging,
and other laboratory tests to determine eligibility for treatment
(Adams et al., 2007). Although advances in diffusion-weighted
MRI technology, novel imaging techniques, analysis, and inter-
pretation have increased the accuracy of differentiating between
ischemic andhemorrhagic stroke (Fiebach et al., 2002),many acute
care facilities arenot equipped toperform this testing andmust rely
on other means of analysis. CT scans, among various other tech-
niques, are reasonably effective but imperfect in detecting cerebral
hemorrhage, and unfortunately none of the available imaging
techniques provide a prognosis for spontaneous hemorrhagic
transformations or complications following thrombolytic therapy.
Due to the complexity of diagnosing stroke, the narrow ther-
apeutic window for treatment and the necessity of differentiating
between stroke sub-types, another approach that has gained popu-
larity is the potential use of blood-borne biomarkers as diagnostic
tools and prognostic indicators. Because there are clear advantages
to this approach in terms of time and feasibility, the identiﬁcation
of a molecular signature may prove valuable as both a diagnostic
tool and a prognostic indicator.
BIOMARKERS
One area of great interest in terms of diagnostic value (and
effectiveness of treatments) is the identiﬁcation of biomarkers.
The major goal is to identify one or more molecules that sig-
nify ICH, or indicate high risk for ICH, that are present in the
systemic circulation of stroke patients upon hospital admission.
This would allow for point-of-care analysis that is relatively quick,
non-invasive and accurate, and therefore could be implemented
into the triage system for acute patients to expedite treatment.
An example, though still arguable, of the potential for biomark-
ers is the detection of speciﬁc β-amyloid fragments in the plasma
of patients displaying CAA-related ICH (Hernandez-Guillamon
et al., 2012), and the hope is to deﬁne the molecular signature for
ICH as well as other stroke sub-types.
In the case of hemorrhagic stroke, several potential biomarkers
have emerged that may be useful for diagnosis of ICH and pre-
diction of hemorrhagic transformation following thrombolytic
therapy (for review, see Foerch et al., 2009). Astroglial-speciﬁc
proteins have been deemed as candidates for acute phase ICH,pre-
sumably due to more rapid injury and blood brain barrier (BBB)
disruption relative to less injurious forms of stroke. For example,
plasma glial ﬁbrillary acidic protein (GFAP) has been reported to
be elevated in ICH patients upon admission relative to those clas-
siﬁed with ischemic stroke or stroke mimics (Foerch et al., 2012),
and pretreatment levels of S100β were shown to predict hemor-
rhagic complications following thrombolysis (Foerch et al., 2007).
Several reports support the use of GFAP as a biomarker based on
reliable detection of acute phase ICH (Foerch et al., 2006), abil-
ity to differentiate from ischemic stroke within 6 h of stroke onset
(Dvorak et al., 2009) and the presence of cleavedGFAPbyproducts,
more speciﬁcally the detectable caspase-cleaved GFAP fragments
proximal to plaque-associated vessels (Mouser et al., 2006).
Importantly, several studies have also validated the use of anti-
bodies generated against protein breakdown products and cleav-
age fragments that are produced following brain injury. Some
examples include antigens generated in response to calpain- and
caspase-mediated cell death (Pineda et al., 2007; Mondello et al.,
2010) and GFAP breakdown products (Papa et al., 2011) that are
elevated in plasma from patients that suffered a traumatic brain
injury. Other biomarkers indicative of BBB injury have shown
promise inpredictinghemorrhage following thrombolysis, includ-
ing matrix metalloproteinase 9 (MMP-9; Montaner et al., 2003)
and cellular ﬁbronectin (Castellanos et al., 2004). However, a
cautionary interpretation of these andother biomarker data is nec-
essary until results are rigorously validated in multi-institutional,
double-blinded studies including patients with various forms of
CNS pathology. This is perhaps the crux of the caveat concerning
biomarkers, and further research into the acute molecular mecha-
nisms of ICH pathology is likely necessary to advance the ﬁeld in
this regard.
Recent efforts aimed at identifying novel proteins that are not
“pan-CNS injury”markersmay yield promising results, though the
ﬁeld continues to lack a consensus molecular signature for ICH.
For example, an ELISA-basedmethod for visinin like protein 1 dif-
ferentiated between healthy subjects and ischemic stroke patients
(Stejskal et al., 2011), although it is not clear whether this protein
is elevated speciﬁcally in response to (ischemic) stroke or CNS
injury in general. Pentraxin 3 was associated with higher mortal-
ity in ischemic stroke patients (Ryu et al., 2012), yet elevations
in this protein are also associated with several cardiovascular risk
factors. Since pentraxin 3 may represent atherosclerotic plaque
burden rather than ischemic stroke per se, differentiation from
plaque-associated ICH and hemorrhagic transformation would
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not be possible. Another study demonstrated that increased levels
of brain natriuretic peptide correlated with functional outcomes
and mortality at 3–6months following cardioembolic stroke but
not other sub-types (Kingwell, 2012), lending support to the
notion that speciﬁcity for individual sub-types is possible.
Based upon the accumulated evidence to date, however, it is
conceivable that the use of a single biomarker will not provide
adequate speciﬁcity to discriminate between ICH and other stroke
sub-types. This point has been recognized and addressed by stud-
ies using biomarker panels, with the goal of enhancing speciﬁcity
by obtaining complementary data in the form of multiple pro-
tein levels. One such example is a panel consisting of MMP-9,
S100β, BNP, and d-Dimer that showed promise by discriminat-
ing between stroke and stroke mimics (Rustici et al., 2011). It
is not clear at this point whether this approach will be fruitful
in improving diagnosis and stroke differentiation, although it is
certainly an area worth pursuing. Improvements in future study
design and additional validation studieswill be important in deter-
mining whether speciﬁc biomarkers or biomarker panels possess
the sensitivity and speciﬁcity to be effective in the clinical setting
(Whiteley et al., 2008).
PRECLINICAL MODELS OF INTRACEREBRAL HEMORRHAGE
The use of animal models has been of great beneﬁt for identify-
ing mechanisms of injury and novel therapeutics. In recent years,
however, the failure of candidate therapeutics in clinical stroke
trials has placed additional pressure on basic scientists to develop
better preclinical models that more closely mimic human condi-
tions. There are several well-accepted models that are commonly
utilized to recapitulate hemorrhagic stroke (Figure 1). Although
there is no perfect model, each is effective in reproducing cer-
tain aspects of the clinical pathology (Table 1). What follows is a
detailed comparison of the various preclinical models, with spe-
cial attention afforded to those aspects which relate to translating
ﬁndings to the clinical setting.
COLLAGENASE MODEL
The collagenase model is one of the more common models of
ICH utilized today. This model entails the injection of between
0.075 and 0.4U of a bacterial collagenase into the brain, typi-
cally into the basal ganglia or striatum. The collagenases degrade
the collagen found in the basal lamina of blood vessels, result-
ing in degraded vessels that become leaky and ultimately rupture
(Rosenberg et al., 1990). The bleeding proﬁle of experimental ICH
beginswithbleeding approximately 10min after injection andpro-
gresses to hematoma between 4 and 24 h later. In this regard, the
hematoma progression in the experimental condition mimics that
which occurs in human ICH (Rosenberg et al., 1990), particu-
larly concerning the expansion observed after initial formation
and rebleeding (Wang and Tsirka, 2005).
FIGURE 1 | Schematic depicts models commonly used to mimic
intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH).
Autologous blood injection involves single- or double injection of autologous
blood, or blood fractions, to generate a hematoma within the brain
parenchyma. Collagenase injection is accomplished through the injection of
recombinant bacterial collagenase to mimic blood extravasation following the
rupture of cerebral arterial vasculature. Striatal balloon inﬂation is utilized to
assess the mass hematoma effect on cellular injury and to evaluate the
consequences of hematoma removal. Models of SAH produce blood
accumulation in the subarachnoid space either by injection into the cistern
magna or perforation of the anterior cerebral artery. Arrows represent
injection route and demarcate the mass hematoma region.
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Table 1 | Comparison of injury mechanisms and characteristics in experimental models of intracerebral and subarachnoid hemorrhage.
Edema and inflammation Lesion characteristics Mechanisms and toxicity
AUTOLOGOUS BLOOD INJECTION: ICH
Inﬂammation increased when fractions contain
lysed RBCs
No lesion expansion Cytotoxic response to blood products mirrors
clinical data
Inﬂammatory response larger than clinical
observations
Lesion maturation is expedited Does not mimic physiological causes of
spontaneous ICH
Edema greater with injection of lysed RBCs Little or no bleeding
Edema peaks faster and resolves earlier than clinical
observations
Injection of blood fractions mimics
maturation of lesion
Limiting injection volume prevents
ventricular hemorrhage and/or SAH
COLLAGENASE INJECTION: ICH
Inﬂammatory effects to collagenase itself Lesion expansion occurs within the ﬁrst 24 h Potential for increased toxicity due to
recombinant enzyme
Inﬂammation and edema peak faster and resolve
earlier than clinical observations
Dose-dependent lesion size Does not mimic spontaneous ICH
Bleeding from in situ vessels Multiple vessel degradation and rupture
Greater tissue loss compared to autologous
model
More extensive, diffuse lesion than
autologous model
Lesion evolution mimics clinical observations
STRIATAL BALLOON INFLATION: ICH
Edema and inﬂammation are reduced due to absence
of blood products within lesion
Lesion reﬂects mechanical injury Only mimics mass effect of expanding
hematoma
Little or no blood products are introduced
into the brain
Cell death due to ischemia from mass effects
Injury is largely due to mass effects and
ischemia
Mimics surgical removal of hematoma
Injury limited to immediate surrounding area
CISTERNA MAGNA BLOOD INJECTION: SAH
Edema and inﬂammation similar to clinical
observations
Reproducible lesion volume Cytotoxic response to blood products mimics
clinical observations
Blood inﬁltration into spinal canal leads to additional
inﬂammation
No bleeding or rebleeding Intracranial pressure less severe than clinical
observationsInjection volume is limited
Excessive volume and pressure causes
blood to enter spinal canal
VESSEL PERFORATION: SAH
Edema and inﬂammation similar to clinical
observations
Variable lesion volume Cytotoxic response to blood products mimics
clinical data
Larger volume of blood in hematoma increases
edema and inﬂammation relative to cistern magna
blood injection
Clinically relevant bleeding proﬁle Does not mimic physiological cause of bleed
Lesion evolution closely mimics clinical
observations
Severity of increase in ICP mimics increase
observed in patients
Mimics aneurysm rupture
The prescription of oral anticoagulant therapy is a common
complication seen in the clinic since it impairs clotting and often
exaggerates bleeding following ICH (Steiner et al., 2006; Foerch
et al., 2008). Thus, the combined model of oral anticoagulant
therapy and collagenase injection mimics this comorbidity for
purposes of identifying ways to circumventing this clinical issue.
The model itself involves the administration of some anticoagu-
lant often prescribed to patients, e.g.,warfarin, at therapeutic levels
prior to the induction of ICH via collagenase injection.
Relevance to the clinical pathology
The collagenase model reproduces some of the pattern of bleed-
ing from in situ vessels seen in the clinical presentation (Wang and
Tsirka, 2005). The fact that the hemorrhage arises from in situ ves-
sels patterns somewhat the spontaneous bleeding found in clinical
ICH. However, because the bleeding is induced by an exogenous
enzyme that degrades the vessels, this model is imperfect for inves-
tigations into the physiological causes of spontaneous ICH. An
additional caveat is that the injection of collagenase leads to the
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breakdown of multiple vessels throughout the effected region,
whereas clinical ICH often results from the rupture of a single
vessel (MacLellan et al., 2008; Qureshi et al., 2009).
The hematoma progression in the collagenase model exhibits
a proﬁle similar to that observed in the clinical setting, with
rebleeding and gradual expansion of the hematoma over the ﬁrst
24 h (MacLellan et al., 2008; Liew et al., 2012). Administration of
oral anticoagulant therapy in combination with ICH mimics the
hemorrhagic response seen in patients that have been prescribed
anticoagulants due to clotting impairments (Steiner et al., 2006).
A caveat of the collagenase model is that the collagenase used to
induce ICH is possibly toxic to other cell types in addition to
the basal lamina, and thus may result in extraneous physiologi-
cal changes that are not representative of the clinical pathology.
Indeed, many believe that recombinant collagenase enzymes are
responsible for heightened inﬂammation and cellular toxicity rel-
ative to the human condition, although this assertion has yet to be
validated experimentally.
As such, while the collagenous model is useful for investigating
mechanisms of neuronal and glial cell death and activation, ﬁnd-
ings should be interpreted with these limitations in mind (Xue
and Del Bigio, 2003). In addition, the model has the potential to
cause excessive damage and hemorrhage if the dose of collage-
nase is too large (Rosenberg et al., 1990). The inclusion of oral
anticoagulant therapy into this ICH model translates quite well to
the human condition despite the reliance upon artiﬁcial induction
rather than spontaneous bleeding from an in situ vessel.
AUTOLOGOUS BLOOD MODEL
At present, the injection of autologous whole blood or blood frac-
tions is one of the most common strategies used to recapitulate
ICH and is one of the oldest models. This model entails collecting
blood from a superﬁcial artery, such as in the tail, and inject-
ing it stereotactically into the brain (Nath et al., 1986). The most
common target for injection is the striatum, as injections into
the cortex can potentially precipitate SAH and further complicate
the already intricate process of ICH (Xue and Del Bigio, 2000b).
There are multiple ways to inject autologous blood into the brain;
the injection can be composed of whole blood, lysed blood, or
red blood cell (RBC) plus different cellular fractions (Xue and Del
Bigio, 2000b; Hua et al., 2002). Administration of different cellular
fractions allows for the investigation of the manner in which each
cell type contributes to mechanisms of injury. Approximately 50–
100μL of whole blood is injected, typically at a rate of 5–10μL per
min.Use of a faster injection rate or larger volume tends to produce
additional damage associated with the mechanical expansion and
even intraventricular hemorrhage (IVH; Yang et al., 1994). Back-
ﬂow of blood along the needle track can also lead to formation of
IVH or SAH, which challenges reproducibility and translational
value.
Relevance to the clinical pathology
Injection of whole blood into the brain translates to the clinic
insofar as the physiological response seen; however, because the
injection in this model is given as more or less a single bolus, there
is little to no expansion of the hematoma as is observed with the
collagenase model. The most signiﬁcant factor is the failure of this
model to produce bleeding from in situ vessels; with no bleeding
from in situ vessels, there are no rebleeding events reminiscent of
those observed in the clinic. One advantage of this model is the
production of inﬂammation and toxicity that somewhat resem-
bles clinical ICH (Xue and Del Bigio, 2000a), although it should
be noted that the inﬂammation that occurs in both the collagenase
model and the autologous blood model is signiﬁcantly higher than
that which has been detected in patients (Qureshi et al., 2009).
The act of injecting blood via a syringe at a ﬁxed rate is often
considerably slower and at lower pressures than bleeding from an
in situ artery, necessarily limiting the translation of this model to
the clinical setting. To address this issue, one strategy would be
to inject the blood at a rate consistent with physiological arterial
pressure to more closely mimic the mechanical force that pro-
duces ICH in patient populations (Nath et al., 1986). Autologous
injection is also hindered by the limited blood volume that can be
injected prior to excessive injury. Since the vast majority of clinical
ICH results from vascular malformations (Qureshi et al., 2001),
each of these injection models suffer from the limitation of no
prior vascular pathology.
Injection of the different fractions of autologous blood leads
to varied responses to the fraction injected (Huang et al., 2002;
Zhao et al., 2009). Following ICH, RBCs begin to lyse soon after
entering the brain parenchyma, releasing their intracellular con-
tents. The injection of lysed blood is utilized to mimic the result of
the breakdown of the blood after the initial hematoma formation,
and simulate a more mature hematoma (Zhao et al., 2009). How-
ever, upon considering the inﬂammatory response, it should be
noted that the injection of lysed RBCs leads to a marked increase
in inﬂammation in the ﬁrst 24 h after ICH. Injection of autolo-
gous blood represents a single bolus event of blood, and because
there is no rebleeding events, the hematoma matures relatively fast
and resolves faster than in the collagenase model. The collagenase
model hematoma requires several weeks to mature, allows for a
longer evaluation time and the maturation pertains more closely
to the clinical model (MacLellan et al., 2008; Wang, 2010). The
lesion size produced in the blood injection model can be variable
due to backﬂow of the blood along the needle track or entrance of
the blood into the ventricles or along the corpus callosum.
This result can be alleviated by employing the double injection
model (Wang et al., 2008). The double injection model entails an
initial injection of a small blood volume that coagulates along the
needle track prior to a second, larger injection to introduce the
hematoma. The coagulation of blood along the needle track alle-
viates the backﬂow of blood along the needle track and alleviates
the need for incorporating heparin, as anticoagulant therapy has
been shown to contribute to hematoma expansion (Flibotte et al.,
2004), mortality (Cucchiara et al., 2008), and rebleeding events
(Vermeer et al., 2002; Matute et al., 2012) in ICH patients. How-
ever, it should be noted that newer pharmacological agents that
are currently under investigation may alleviate adverse outcomes
associated with traditional therapies (for review, see Moussouttas,
2012).
BALLOON INFLATION MODEL
The balloon inﬂation model entails the insertion of an emboliza-
tion balloon into the brain, most often in the same location
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used for the previous two models. The volume of the balloon
and the length of inﬂation are easily reproduced. The resulting
lesion is directly proportional to the size of the inﬂation, allowing
for manipulation of injury severity. The most common volume
injected into the balloon is approximately 300μL, injected over
the course of 1min (Lopez Valdes et al., 2000). The balloon model
is utilized to investigate the mass effect of the hematoma. In con-
trast to the injection ICH models, the balloon model produces
injury that is purely mechanical and lacks introduction of blood
or metabolites resulting from RBC lysis. Therefore, this model is
valuable for studying hematoma mass effects in isolation since cell
death results primarily from mechanisms initiated by ischemia
alone (Lopez Valdes et al., 2000).
Relevance to the clinical pathology
The balloonmodel replicates themass effects seen in the expansion
of the hematoma in ICH,and is a valuable tool for investigating the
effects of removal of the hematoma. This can be achieved simply
by deﬂating and withdrawing the balloon from the skull. This is
particularly relevant to clinical treatment strategies, as a signiﬁcant
portion of the patients presenting with ICH have some form of
surgical intervention for hematoma removal (Lopez Valdes et al.,
2000; Huang et al., 2002; Thai et al., 2006). However, since the
balloon model is relatively limited in the scope of area affected,
as there are no blood products introduced into the lesion, it is
not possible to evaluate the blood-derived toxicity mechanisms
involved in ICH. The absence of blood products in the lesion
allows for investigation of the mechanisms of neuronal death in
isolation. The solely mechanical nature of the injury in this model
translates well to the clinical data of surgical intervention. How-
ever, ﬁndings should be interpreted considering the limitation that
ICH injury represents a complex interplay of mass effects and
deleterious cascades, many of which this model does not address.
SUBARACHNOID HEMORRHAGE MODEL
Currently, experimental modeling of SAH is achieved through
either injection of blood into the cisternae magna or the perfora-
tion of intracranial arteries. Methodologically, the blood injection
model is similar to the autologous blood injection model above
with the exception of the speciﬁc location of injection. The perfo-
ration model is a modiﬁcation of the intraluminal ﬁlament model
used formiddle cerebral artery occlusion in experimental ischemic
stroke (Park et al., 2008). The perforation model entails the inser-
tion of a ﬁlament to the proximal anterior cerebral artery (ACA),
advancement through the wall of the ACA and subsequent with-
drawal to induce SAH. A majority of SAH cases arise from the
rupture of aneurysms, and while both models of SAH reproduce
the accumulation of blood into the subarachnoid space, the perfo-
ration model more accurately mimics the hemorrhage itself (Park
et al., 2008; Lee et al., 2009).
Relevance to the clinical pathology
The injection and perforation models are both effective means of
investigating of the mechanisms of injury resulting from blood
accumulation in the subarachnoid space. However, with the injec-
tion model, the blood often spreads into the spinal canal, a condi-
tion not observed in the clinic (Lee et al., 2009). Another caveat of
the injection model is that the mechanism of hemorrhage induc-
tion does not mimic aneurysm rupture. Despite these issues, the
injection model beneﬁts from the fact that hemorrhage volume
is controllable and highly reproducible experimentally. Between
the two models, the perforation model most closely mimics the
mechanisms and pattern of bleeding observed in the clinic. This
method also resembles aneurysmrupture,with initial bleeding and
rebleeding events leading to gradual evolution of the hematoma
(Park et al., 2008), and is a more accurate mimic of the intracra-
nial pressure associated with clinical ICH. However, a caveat that
arises in the perforation model is the highly variable hemorrhage
size observed experimentally. Therefore, although vessel perfora-
tion is effective in recapitulating some of the clinical observations,
it can be problematic when evaluating experimental treatments
due to difﬁculty in achieving reproducible hemorrhage volume
(Lee et al., 2009).
OUTCOME MEASURES IN PRECLINICAL MODELS
In addition to the type of model employed, a major determi-
nant of the future success of preclinical models, in terms of both
experimental efﬁcacy and translational value, is the evaluation
of outcomes. Various measures have been used in the assess-
ment of injury and therapeutic efﬁcacy, encompassing elements
of cellular injury, brain edema, and performance on tasks that
require neurological and sensorimotor faculties. Recently there
has been an added emphasis on multiple outcome measures that
assess both histological and behavioral recovery, as the benchmark
for efﬁcacy appears to be shifting from histological to functional
improvement.
NEUROHISTOLOGICAL OUTCOMES
Most recent studies have evaluated both functional and histolog-
ical outcomes. Of the histological outcomes, the most commonly
used have been hematoma volume, quantiﬁcation of neuronal
loss, and immunohistochemistry probing for various markers of
inﬂammation and immune cell responsiveness (Xi et al., 2006;
Kirkman et al., 2011). Certain patterns have emerged from these
investigations. For example, inﬂammation and edema are greater
in the collagenase and blood injection models when compared to
the clinical data (Wasserman et al., 2008;Qureshi et al., 2009; Kirk-
man et al., 2011). The time course for edema and inﬂammation
in experimental ICH is much faster than the onset and duration
observed in patients with ICH (Xi et al., 1998; Xue and Del Bigio,
2000a, 2003; Huang et al., 2002). Additionally, MRI studies of the
time course of infarct expansion reveal that only in the collagenase
model does the lesion continue to mature for several weeks, while
the blood injection model takes considerably less time to achieve
complete hematoma expansion (MacLellan et al., 2010). These
ﬁndings are particularly relevant since clinical data suggests that
the hematoma takes several weeks to months to resolve without
surgical intervention (Qureshi et al., 2009).
Between the two models, the collagenase model causes signiﬁ-
cantly greater loss of neurons compared to the autologous blood
model (MacLellan et al., 2010). Hematoma expansion is a sig-
niﬁcant factor in human ICH and is present in most patients
presenting with ICH. To date, the only model that appears to
reproduce some clinical hematoma expansion is the collagenase
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model. However, the loss of tissue in the collagenase model is far
greater than that seen in the autologous blood model. Addition-
ally,damage caused by the needle is signiﬁcantwhenusing even the
smallest needle (McCluskey et al., 2008), and therefore presents an
additional caveat in the translation of injection models. Thus, the
signiﬁcant amount of damage caused by the needle can inﬂuence
all other evaluated factors and must be taken into account when
interpreting results from preclinical injection studies.
Secondary injury largely results from hematoma expansion.
The contributing factors to this delayed injury phase include
inﬂammation, cytotoxicity of blood products, oxidative stress,
and inﬁltrating immune cells (Wang and Doré, 2007). In exper-
imental ICH, edema, and inﬂammation are preceded by BBB
breakdown, which leads to inﬁltration of peripheral immune cells
and enhanced pro-inﬂammatory signaling (Aronowski and Zhao,
2011). Themost commonmethod of measuring edema is by deter-
mining the difference between the wet and dry weight of the brain,
as weight increases proportionally with ﬂuid extravasation. Edema
peaks at approximately 3 days and resolves within several days
(Xi et al., 2006). The time course of edema in the clinical set-
ting is slightly different, peaking at approximately 14 days after
ICH (Staykov et al., 2011). This temporal difference between the
clinical data and the experimental data is due in part to differing
amounts of white matter in rodents and humans (Adeoye et al.,
2011).
The inﬂammatory response to ICH involves a complex inter-
play of resident immune cell activation, peripheral immune cell
extravasation, and cellular signaling. The activation of resident
microglia and astrocytes is accompanied by extravasation of
neutrophils, peripheral macrophages, and RBCs into the brain
parenchyma. Immune cells produce various cytokines and pro-
teases (Power et al., 2003) that contribute to a pro-inﬂammatory
microenvironment (Aronowski and Zhao, 2011). Although acti-
vated microglia and neutrophils play a key role in hematoma
resolution, both cell types produce inﬂammatory mediators and
reactive oxygen species (ROS) that may exacerbate injury follow-
ing ICH. Elevations in oxidative stress and cytokine production
occur within hours following ICH (Wang and Doré, 2007) and are
generally considered to be indicators of inﬂammation. Oxidative
stress results from ROS production by microglia, macrophages,
and neutrophils, as well as the release of free iron from hemoglo-
bin degradation (Aronowski and Zhao, 2011). TNFα and IL-1β are
among the most common cytokines investigated, most likely due
to their putative pro-inﬂammatory roles, although alterations in
numerous other cytokines and chemokines have beendocumented
(Wang and Doré, 2007).
The net effect of this immune cell response remains unknown,
yet the involvement of these cells is considered by many to exac-
erbate ICH injury. At present, few studies have deﬁnitively shown
more than an temporal association between activated immune
cells, the release of inﬂammatorymediators and progressive injury.
Nonetheless, immune cell activation is commonly utilized as an
indicator of injury severity. This is generally accomplished through
immunohistochemical quantiﬁcation with antibodies generated
against cell surface antigens selectively expressed by neutrophils
(myeloperoxidase), microglia/macrophages (CD11b, ED1, and/or
Iba1), and reactive astrocytes (GFAP).With regard to the detection
of activated microglia/macrophages, cell surface antigen expres-
sion is assessed in conjunction with morphological analysis, as
activated cells display an amoeboid morphology relative to the
squamous or ramiﬁed phenotypes characteristic of resting cells.
It should be noted that these cell surface antigens are differen-
tially expressed on various immune cells depending upon the
maturation and activation state, and there is currently no cell
surface antigen that can be exploited for absolute identiﬁca-
tion of resident microglia relative to peripheral, extravasating
monocytes/macrophages.
Because a multitude of cytokines, chemokines, and
prostaglandins contribute to the overall inﬂammatory state of the
cerebral microenvironment, it is likely that a combination of sig-
nals drives the neural sequelae. Therefore, future in vivo studies
investigating these temporal response proﬁles in conjunction with
mechanistic in vitro approaches may improve our general under-
standing of the ways in which this concerted signaling ultimately
contributes to neural injury following ICH.
FUNCTIONAL OUTCOMES
While it is important to assess hematoma volume, expansion,
and neuronal loss, most ICH patients have signiﬁcant neurolog-
ical and functional deﬁcits that are often permanent (Cramer,
2008; Qureshi et al., 2009). Because the bench mark for preclini-
cal efﬁcacy involves restoration of function, behavioral outcomes
are currently viewed as a critical component of determining the
potential of novel therapies. The functional responses in experi-
mental ICH mimic those seen in the clinic with some correlation
to lesion size, location, and degree of deﬁcit (Hua et al., 2002).
The most common methods for evaluating functional outcomes
involve a series of behavioral tests that are scored on a neurological
scale. This scale allows for the calculation of a neurological deﬁcit
score (NDS) that can be used for relative comparisons of neurobe-
havioral impairment (Hua et al., 2002). Other testing modalities
involve the assessment of ability to perform tasks that require
motor coordination and/or cognition. For ICH, some of the most
common behavioral tests currently used involve limb placement,
balance, and circling. Functional recovery is most often exam-
ined relatively shortly after ICH, and most published studies have
demonstrated increases in recovery of function in the behavioral
tests and improvement in NDS. While this mimics the recovery of
simple tasks in patients, it does not model long-term deﬁcits (Hua
et al., 2006).
One explanation for the quick recovery in the rodent model
is the relatively small amount of white matter and resolution of
edema (Fisher et al., 2009). Between some of the commonly used
collagenase and autologous blood injection models, the time for
neurological deﬁcits to return to normal was longer in the colla-
genase model (MacLellan et al., 2008). However, behavioral tests
that require more advanced sensorimotor functioning are prefer-
able when attempting to mimic the human condition. Rodent
studies have documented long-termbehavioral deﬁcits using com-
mon ICH models (≥1month following ICH; Beray-Berthat et al.,
2010), although these tests may not possess the sensitivity to detect
differences in the severity of injury (MacLellan et al., 2006).
Despite their utility, behavioral tests, and NDS are poor pre-
dictors of hematoma size, with location having a more substantial
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impact on NDS. Importantly, none of the above tests address cog-
nitive function in ICH. In fact, few experimental studies have
rigorously examined the cognitive impact of ICH despite evi-
dence that ICH patients experience cognitive deﬁcits (Su et al.,
2007; MacLellan et al., 2009). The paucity of reproducible cog-
nitive assessments has been attributed, in part, to confounding
interpretation of testing that involves mixed motor and cognitive
components. However, mixed results within the literature are per-
haps more problematic when attempting to resolve issues related
to duration of deﬁcit, type of deﬁcit, and the degree of functional
restoration that can be attributed to spontaneous recovery. These
issues may be alleviated by future studies from multiple laborato-
ries that have adopted standardized behavioral testing procedures.
Indeed, a major drawback of behavioral testing in general, and
particularly NDS scoring methods, is the subjective nature of
assessment. Therefore, it will be imperative to adopt standardized
testing procedures that employ more objective means of assessing
functional outcomes.
IMPROVING TRANSLATIONAL VALUE
One of the major limitations of preclinical studies is the degree
of external validity, which concerns whether results obtained from
sample populations (and in this case, experimental models) can
be predictive of those in patient populations. Because the experi-
mental method is based heavily upon maximizing internal validity
within a particularmodel or paradigm,attempts to control all vari-
ables other than that being investigated necessarily limit the gen-
eralizations that can be made regarding effects on heterogeneous
populations.
Although this caveat is inherent and essentially unavoidable
when attempting to address speciﬁc effects, the translational value
of experimental studies can be improved by expanding the overall
scope of investigations (Figure 2). Several reports have prescribed
methods and strategies to improve the translational value of pre-
clinical stroke models (STAIR, 1999; Fisher et al., 2009), including
ICH (Kirkman et al., 2011; MacLellan et al., 2012). The following
suggestions are speciﬁcally relevant to risk factors and diagnostic
strategies that should be considered in future efforts to improve
patient outcomes following ICH.
MODELING RISK FACTORS
Several underlying risk factors have been identiﬁed for stroke, in
general, and can be applied to ICH. However, in the case of hem-
orrhage, it will be of particular importance to identify factors that
(1) may represent a unique or increased risk for ICH, and (2)
can be incorporated into experimental models, thereby improv-
ing the likelihood of successful translation into the clinical setting.
Although initial studies in young, healthy animals are preferred for
initial screening of novel therapies, subsequent studies including
comorbid conditions must be conducted to validate results prior
to clinical application.
Hypertension and diabetes
In contrast to the many purported proximal causes of ICH injury,
the incontrovertible physical cause of vascular rupture, arterial
pressure, has not been modeled effectively at present. Because high
blood pressure is one of the major risks for stroke (Roger et al.,
FIGURE 2 | Diagram depicts the suggested strategy for improving
translational studies using preclinical models. For testing novel
therapeutics, initial experiments that do not show efﬁcacy should be
re-evaluated for methodological soundness, and in the absence of
experimental ﬂaws, these treatment strategies should be abandoned.
Studies that demonstrate efﬁcacy in single models, sexes, or species
should be regarded as preliminary and subsequently validated with more
rigorous, comparative studies. The suggested validation approach involves
comparisons between sexes, distinct ICH models, aged animals, and
comorbid conditions that are common in the clinical setting prior to testing
in higher order species. Due to the heterogeneity of patient populations,
mixed results from validation studies should be subjected to additional
evaluations, when appropriate, for application to speciﬁc patient cohorts.
Negative data should be reported in all instances to guide the ﬁeld with
future investigations.
2012) and is associated with hemorrhage following thrombolytic
therapy (Butcher et al., 2010), future studies should incorporate
strategies to mimic physiologically relevant blood pressure, as well
as high blood pressure, and conduct comparative studies to assess
outcomes and treatment efﬁcacy.
The stroke-prone spontaneously hypertensive rat has been
widely used to model high blood pressure, and demonstrates
increased susceptibility to ICH(Wuet al., 2011).Although thephe-
notype may introduce additional caveats such as cardiac abnor-
malities andother unique features that contribute to stroke pathol-
ogy (for review, see Bailey et al., 2011), modeling hemorrhage in
this or other spontaneous models of hypertension-induced ICH
(Iida et al., 2005) has some advantages. For example, hypertension
is inherent in the species and/or induced through the diet, there-
fore there is no need to induce the phenotype with pharmaceutical
agents that could confound interpretation of the results. Since car-
diovascular disease is a systemic problem, these phenotypes are a
closer representation of the comorbidity in patients compared to
relatively healthy animals. The use of these models also allows for
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investigating interactions between novel treatments and currently
prescribed medications, which could eliminate red herrings that
show preclinical efﬁcacy when administered alone but produce
toxicity in combination with other pharmaceutical agents.
In light of potential caveats with hypertensive animals, another
approach would be to employ the autologous injection model
using a ﬂow rate that more closely mimics physiological arter-
ial pressure. However, it is conceivable that increased injection
pressure could produce injury severity that exceeds that which
is typically observed in clinical ICH. It is noteworthy that the
autologous blood model lacks the hematoma expansion that is
characteristically observed in patients, and therefore this approach
may recapitulate the human pathology, similar to the collage-
nase model, while lacking the excessive inﬂammatory compo-
nent of recombinant collagenase injection. Future investigations
are needed to determine the feasibility and relevance of this
approach.
Consistentwith a role for exacerbating ICH, recent data showed
that diabetic and hyperglycemic rats are more susceptible to hem-
orrhage and less responsive to thrombolytic therapy (Won et al.,
2011; Fan et al., 2012). Similar effects have been reported in
diabetic mouse models (Chen et al., 2011; Liu et al., 2011). At
present, there are an increasing number of studies incorporating
the diabetic comorbidity into preclinical ICH models. Continued
investigations into this link will likely increase our understanding
of the precipitating factors leading to cerebral hemorrhage.
Cerebral amyloid angiopathy
As in the patient population, amyloid deposition produces vascu-
lar pathology in animal models. The use of genetically modiﬁed
mice will likely be important in gaining a better understanding
of CAA progression, as shifting the production of different β-
amyloid species inﬂuences the tissue localization and degree of
deposition (Herzig et al., 2004). There are several mouse models
that exhibit cerebral vascular pathology similar to that observed
in CAA patients, including weakened cerebral vasculature, age-
related plaque accumulation, microbleeding, and macrohemor-
rhage (Van Dorpe et al., 2000; Christie et al., 2001; Kimchi et al.,
2001; Winkler et al., 2001). Transgenic studies have conﬁrmed a
role for the known risk factor epsilon4 apolipoprotein E allele
(Fryer et al., 2003) and demonstrated efﬁcacy in reducing plaque
load and microhemorrhage by targeting ApoE interactions (Yang
et al., 2011). These and other encouraging results (for review,
see Viswanathan and Greenberg, 2011) highlight the potential
of experimental models in advancing diagnosis and treatment of
CAA-related ICH.
BIOMARKER SCREENING
A critically important issue for effective treatment is the ability to
diagnose ICH accurately and expeditiously. Despite advancements
in imaging techniques, the expenses associated with the most
recent technologies and the requirement for preliminary evalu-
ations will render many patients unable to beneﬁt from imaging
analyses. To increase the efﬁciency and scope of diagnostic testing,
themost promising strategymay be the development of biomarker
panels that can be used to screen patients for molecular signatures
that deﬁne the type and/or severity of injury.
Because basic science research provides the foundation for
mechanistic inquiry and beneﬁts from greater experimental con-
trol relative to clinical studies, preclinical investigations should
incorporate assessments of promising biomarkers in attempts to
generatemolecular pathological blueprints for the resulting seque-
lae. The use of panels, as opposed to single protein targets, is likely
to be of greater beneﬁt due to the multifactorial molecular cas-
cades associated with various forms of neuropathology, including
ICH. In the case of brain trauma, a major cause of ICH, such
panels were developed (Mondello et al., 2011a) to assess a variety
of brain-associated proteins that are elevated in plasma, includ-
ing dendritic marker MAP-2, myelination marker MBP, neuronal
marker NSE, gliosis marker GFAP, and neuronal ubiquitination
markerUCH-L1 (Brophy et al., 2011;Mondello et al., 2011b). Ani-
mal studies should pursue these quantitative analyses with other
brain- or vascular-associated proteins and continue the search
for proteolytic cleavage products of brain antigens. In addition
to identifying novel proﬁles for clinical screening, experimen-
tal investigations should incorporate assessments of biomarkers
that have shown promise in the clinical setting, such as those
mentioned, as means of validating the translational value of the
models.
RIGOROUS METHODOLOGICAL PRACTICES
Recommendations for good general practices in experimental
ischemic stroke research methodology have been detailed by the
Stroke Therapy Academic Industry Roundtable (STAIR, 1999;
Fisher et al., 2009). These practices have also been endorsed in
recent reviewsbyKirkmanet al. (2011) andMacLellan et al. (2012),
and are consistent with the priorities described by the National
Institute of Neurological Disorders and Stroke (NINDS, 2005)
and the American Heart and Stroke Association. These prescrip-
tions underscore the essential problem of experimental research,
the quality of which ultimately hinges upon maximizing internal
validity by evaluating the independent variable through experi-
mental control of other confounding variables. In the laboratory,
this method is critical to determine causality. In terms of exter-
nal validity, however, it lacks the ability to assess other comorbid
conditions that are important determinants of whether clinical
efﬁcacy can be achieved.
As a consequence, studies need to be expanded to include
various groups that represent all of the conditions and comor-
bidities present within mixed patient populations. For example,
sex differences need to be investigated by comparing male and
female animals. In these investigations, attention should be paid to
estrous cycle when evaluating mechanisms of injury and recovery.
In treatment studies, physiological parameters need to be moni-
tored to determine the mechanisms responsible for the observed
effects, andwhether the compounds produce adverse physiological
responses (i.e., increased blood pressure) that would contraindi-
cate use in speciﬁc patient populations. Due to the low body
mass of rodents, acute changes in temperature and body weight
should be monitored closely, as even slight changes can produce
substantial alterations in physiology and behavior.
For assessment of efﬁcacy, histological outcomes need to be
measured in conjunction with behavioral batteries that include all
aspects of clinical ICH pathology, including motor and cognitive
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disturbances, at both short- and long-term time points following
ICH. When evaluating behavioral outcomes, it is also important
to consider circadian rhythms. Because rodents exhibit a noctur-
nal active cycle, animals should be housed on a reverse light cycle
to provide a more accurate measure of motor activity and cog-
nition. Toxicity markers should be evaluated following treatment,
and successful strategies should be validated in multiple models
due to differences in the degree of hematoma expansion, neuroin-
ﬂammation, and cellular injury (Xue and Del Bigio, 2003). Sample
size calculations should be conducted to ensure adequate power to
detect signiﬁcant differences,and also to limit thepotential for false
positives that can result from inﬂated group sizes.When appropri-
ate, animal exclusion should be reported, including the number
of animals excluded, the cause for removal from the study, and
the mortality rate resulting from surgical or other manipulations.
Evaluations should also be conducted using all possible strate-
gies to reduce experimenter bias, including random assignment to
experimental groups, double-blinded outcome assessments, and
a priori determinations of exclusion criteria.
As mentioned, the inclusion of phenotypes representative of
prevalent comorbidities (diabetes, CAA) and risk factors (hyper-
tension, age) are perhaps most crucial in improving the trans-
lational value of future studies involving ICH. The development
of newer models that more closely mimic the underlying human
pathology will also be of great beneﬁt for future investigations. A
recent study described a new transgenic mouse model in which
animals develop AVMs that produced debilitating phenotypes,
including severe motor disturbances and lethality (Milton et al.,
2012). In this regard, the utilization of knockouts and trans-
genic animals, in conjunction with other recommendations, could
provide substantial advancements in the ﬁeld.
By combining genetically modiﬁed methods with clinically rel-
evant phenotypes, we have recently demonstrated a link between
prostaglandin receptor function and β-amyloid-mediated stroke
injury (Zhen et al., 2011). Similar approaches will likely increase
our knowledge of injury mechanisms, further address the selec-
tivity of novel treatments and identify additional targets for ther-
apeutic interventions. Investigations with aged animals following
the completion of studies in young, healthy animals is one recom-
mendation which, given the clinical scope of ICH, will be critical
in translating effective preclinical results into clinical therapeutic
efﬁcacy. Importantly, this combined approach should maximize
the potential of elucidating causal factors, such as the role of cere-
bral arterial β-amyloid deposition (Lee et al., 2012) in hemorrhage
predisposition, and identifying biomarkers that can be applied to
speciﬁc patient populations upon presentation in the clinic.
In conjunction with these approaches, future studies will bene-
ﬁt from the utilization of enhanced image technologies that allow
for live, in vivo brain imaging. MRI was demonstrated to corre-
late with histological outcomes following ICH (Del Bigio et al.,
1996). Preclinical models should attempt to incorporate this and
other imaging techniques, as these methods would provide greater
opportunity for correlating biomarkers with injury progression
and/or treatment efﬁcacy. Finally, validation studies in higher
order species is necessary due to the limitations of rodent models.
For example, autologous blood injection into the pig brain allows
for more gradual hematoma development, greater reproducibility,
and more closely mimics the human condition due to the greater
abundance of white matter (Wagner et al., 1996). The Interna-
tional Classiﬁcation of Functioning, Disability and Health (ICF)
has also emphasized the importance of environmental factors
that interact with biological processes to inﬂuence susceptibility
and patient outcomes. These classiﬁcations incorporate various
inﬂuences related to body function, biological structure, activities
associated with daily living, access/utilization of various health
care resources and other sociodemographic characteristics that
are poorly modeled in rodents (Kucukdeveci et al., 2011; Quin-
tas et al., 2012). Therefore, expanding the use of ICH models in
higher order species will also provide more opportunities to assess
factors that reﬂect psychosocial contributions to susceptibility and
recovery.
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